Lahiji Arian Pourmehdi, Mortazavi Mojgan, Tirani Shahnaz Amani, Moeinzadeh Firouzeh, Bidaki Ehsan Zarea, Naini Afsoon Emami, Faghihi Gita, Toghyani Arash, Farajzadegan Ziba
Department of Preventive Medicine and Community Health, University of Texas Medical Branch, USA.
Department of Internal Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
J Res Pharm Pract. 2018 Oct-Dec;7(4):195-199. doi: 10.4103/jrpp.JRPP_18_64.
Pruritus is a prevalent skin condition in end-stage renal disease patients. Omega-3 fatty acids have been shown to reduce pruritus in hemodialysis patients. Our objective was to assess the effect of 3 g/day omega-3 supplementation on pruritus among continuous ambulatory peritoneal dialysis (CAPD) patients.
In this two-period, two-sequence crossover randomized clinical trial, 40 eligible subjects (CAPD patients who complained of pruritus for more than 8 weeks) were randomized to 3 g of omega-3 ( = 20) or identical placebo capsules ( = 20) for 4 weeks. After a wash-out period of 6 weeks, patients were crossed over to the alternate treatment option. Pruritus intensity was assessed using the visual analog scale (VAS) at baseline, 2-and 4-weeks post-intervention in each study period. Both patients and investigators were blinded to the study protocol.
No significant carry-over effect was detected. The mean pruritus score (VAS) in the omega-3 group compared with placebo group after the first (-3.02 vs. -0.48, < 0.001) and second (-4.09 vs. -0.43, < 0.001) intervention periods showed higher significant decrease.
In summary, omega-3 supplementation is an effective treatment for pruritus alleviation in CAPD patients. Further studies are needed to determine the mechanisms underlying antipruritic effects of omega-3.
瘙痒是终末期肾病患者中普遍存在的皮肤问题。ω-3脂肪酸已被证明可减轻血液透析患者的瘙痒症状。我们的目的是评估每天补充3克ω-3对持续非卧床腹膜透析（CAPD）患者瘙痒的影响。
在这项两阶段、双序列交叉随机临床试验中，40名符合条件的受试者（抱怨瘙痒超过8周的CAPD患者）被随机分为两组，一组服用3克ω-3（ = 20），另一组服用相同的安慰剂胶囊（ = 20），为期4周。经过6周的洗脱期后，患者交叉接受另一种治疗方案。在每个研究阶段的基线、干预后2周和4周，使用视觉模拟量表（VAS）评估瘙痒强度。患者和研究人员均对研究方案不知情。
未检测到显著的残留效应。在第一个（-3.02对-0.48， < 0.001）和第二个（-4.09对-0.43， < 0.001）干预期后，ω-3组的平均瘙痒评分（VAS）与安慰剂组相比，下降幅度更显著。
总之，补充ω-3是缓解CAPD患者瘙痒的有效治疗方法。需要进一步研究以确定ω-3止痒作用的潜在机制。
